Scarica l'app Stockscreener
85.04
0.40%
-0.34
Dopo l'orario di chiusura:
85.10
0.06
+0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$85.38
Aprire:
$85.9
Volume 24 ore:
9.09M
Relative Volume:
1.94
Capitalizzazione di mercato:
$263.74B
Reddito:
$56.53B
Utile/perdita netta:
$8.32B
Rapporto P/E:
31.94
EPS:
2.6622
Flusso di cassa netto:
$8.49B
1 W Prestazione:
+1.66%
1M Prestazione:
+4.70%
6M Prestazione:
+27.38%
1 anno Prestazione:
+9.72%
Intervallo 1D:
$84.99
$86.38
Intervallo di 1 settimana:
$83.84
$86.57
Portata 52W:
$61.24
$86.57
Astrazeneca PLC Stock (AZN) Company Profile
Nome
Astrazeneca PLC
Settore
Industria
Telefono
44 20 3749 5000
Indirizzo
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Confronta AZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
85.04 | 264.72B | 56.53B | 8.32B | 8.49B | 2.6622 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca PLC Borsa (AZN) Ultime notizie
AstraZeneca Lifts US Plant Investment to $4.5 Billion to Boost Drug Manufacturing - Yahoo
AstraZeneca to Invest $4.5 Billion in New US Manufacturing Facility - MarketScreener
AstraZeneca breaks ground on enormous $4.5bn Virginia manufacturing plant - BioProcess International
AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity DrugsAstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca boosts investment in Virginia plant (AZN:NASDAQ) - Seeking Alpha
AstraZeneca to invest $4.5 billion in Virginia manufacturing facility By Investing.com - Investing.com South Africa
AstraZeneca to invest $4.5B in Virginia facility - breakingthenews.net
AstraZeneca ups investment at new Virginia facility to USD4.5 billion - MarketScreener
AstraZeneca to Boost Spending on Virginia Plant by $500 Million to $4.5 Billion - MarketScreener
AstraZeneca (AZN) Invests $4.5B in New Virginia Facility to Boos - GuruFocus
AstraZeneca to increase investment & scope of Virginia manufacturing facility to $4.5 bln - MarketScreener
AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump - MarketScreener
3,600 Jobs: AstraZeneca Expands Virginia Investment to $4.5B, Adds ADC Cancer Manufacturing - Stock Titan
Turbine Launches Collaboration with Astrazeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener
What machine learning models say about AstraZeneca PLC Depositary ReceiptWeekly Market Outlook & High Accuracy Buy Signal Tips - newser.com
AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Dru - GuruFocus
Volume spikes in AstraZeneca PLC Depositary Receipt stock – what they meanWeekly Stock Recap & Real-Time Market Sentiment Alerts - newser.com
Algen inks $555m AstraZeneca partnership for AI-powered drug discovery - BioXconomy
Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener
Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary Receipt2025 Price Action Summary & AI Driven Price Forecasts - newser.com
Will AstraZeneca PLC Depositary Receipt bounce back from current supportEarnings Risk Report & High Yield Stock Recommendations - newser.com
AstraZeneca PLC $AZN Shares Sold by Prime Capital Investment Advisors LLC - MarketBeat
AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - MSN
AstraZeneca PLC Depositary Receipt recovery potential after sell off2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com
AstraZeneca PLC Depositary Receipt stock momentum explained2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
Stock of the Week: Is AstraZeneca a Buy After Share Price Jump? - Morningstar Canada
Barclays Keeps AstraZeneca at Overweight, Expects 'Resilient' Q3 Results - MarketScreener
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance
What AstraZeneca Can Teach Us About Scaling Innovation Through Ecosystem Collaboration - MarketScreener
AstraZeneca Shares Surge 14% as Investment Pause Spurs Fresh Valuation Debate - Yahoo
Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock - sharewise.com
AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension - Benzinga
Another Baxdrostat Success Takes Pressure Off AstraZeneca - insights.citeline.com
AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension - MarketScreener
AstraZeneca (LSE:AZN): Exploring Valuation as Shares Move Steadily Higher - Yahoo Finance
AstraZeneca PLC $AZN Stock Holdings Lowered by Meitav Investment House Ltd. - MarketBeat
AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus
AstraZeneca Reports Positive Bax24 Trial Results for Hypertension - AskTraders.com
AstraZeneca Says Phase 3 Trial of Baxdrostat Meets Endpoint in Resistant Hypertension - MarketScreener
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
AstraZeneca reports Phase III trial success for baxdrostat in hypertension - Investing.com
AstraZeneca PLC Announces Baxdrostat Demonstrates A Statistically Significant and Highly clinically meaningful Reduction in 24-Hour Systolic Blood Pressure Compared with Placebo - MarketScreener
AstraZeneca drug baxdrostat cuts blood pressure in key late-stage trial - MarketScreener
AstraZeneca and Daiichi’s Datroway trumps chemo in first-line breast cancer - Clinical Trials Arena
D.B. Root & Company LLC Cuts Stake in AstraZeneca PLC $AZN - MarketBeat
BreakingviewsAstraZeneca’s New York shift augurs London exodus - Reuters
AstraZeneca blood pressure drug succeeds in late-stage trial - Financial Times
AstraZeneka presents results for patients with resistant hypertension - MarketScreener
AstraZeneca’s experimental hypertension drug shows promising results - Investing.com
AstraZeneca’s baxdrostat hits key goal in major blood pressure trial - Proactive financial news
AstraZeneca says baxdrostat met primary endpoint in BAX24 Ph3 trial - MarketScreener
Astrazeneca PLC Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):